You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameTelmisartan
Accession NumberDB00966  (APRD01247)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionTelmisartan is an angiotensin II receptor antagonist (ARB) used in the management of hypertension. Generally, angiotensin II receptor blockers (ARBs) such as telmisartan bind to the angiotensin II type 1 (AT1) receptors with high affinity, causing inhibition of the action of angiotensin II on vascular smooth muscle, ultimately leading to a reduction in arterial blood pressure. Recent studies suggest that telmisartan may also have PPAR-gamma agonistic properties that could potentially confer beneficial metabolic effects.
Structure
Thumb
Synonyms
4'-((1,4'-Dimethyl-2'-propyl(2,6'-bi-1H-benzimidazol)-1'-yl)methyl)-(1,1'-biphenyl)-2-carboxylic acid
4'-((4-Methyl-6-(1-methyl-2-benzimidazolyl)-2-propyl-1-benzimidazolyl)methyl)-2-biphenylcarboxylic acid
4'-[(1,4'-Dimethyl-2'propyl[2,6'-bi-1H-benzimidazol]-1'-yl)methyl]-[1,1'-biphenyl]-2-carboxylic acid
4'-[(1,7'-Dimethyl-2'-propyl-1H,3'h-2,5'-bibenzimidazol-3'-yl)methyl]biphenyl-2-carboxylic acid
BIBR 277
Micardis
Telmisartan
External Identifiers
  • BIBR 277
  • BIBR 277SE
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Act TelmisartanTablet40 mgOralActavis Pharma Company2012-10-19Not applicableCanada
Act TelmisartanTablet80 mgOralActavis Pharma Company2012-10-19Not applicableCanada
Auro-telmisartanTablet40 mgOralAuro Pharma Inc2016-04-08Not applicableCanada
Auro-telmisartanTablet80 mgOralAuro Pharma Inc2016-04-08Not applicableCanada
KinzalmonoTablet40 mgOralBayer Pharma Ag1998-12-16Not applicableEu
KinzalmonoTablet20 mgOralBayer Pharma Ag1998-12-16Not applicableEu
KinzalmonoTablet80 mgOralBayer Pharma Ag1998-12-16Not applicableEu
KinzalmonoTablet40 mgOralBayer Pharma Ag1998-12-16Not applicableEu
KinzalmonoTablet20 mgOralBayer Pharma Ag1998-12-16Not applicableEu
KinzalmonoTablet80 mgOralBayer Pharma Ag1998-12-16Not applicableEu
KinzalmonoTablet40 mgOralBayer Pharma Ag1998-12-16Not applicableEu
KinzalmonoTablet80 mgOralBayer Pharma Ag1998-12-16Not applicableEu
KinzalmonoTablet40 mgOralBayer Pharma Ag1998-12-16Not applicableEu
KinzalmonoTablet20 mgOralBayer Pharma Ag1998-12-16Not applicableEu
KinzalmonoTablet40 mgOralBayer Pharma Ag1998-12-16Not applicableEu
KinzalmonoTablet80 mgOralBayer Pharma Ag1998-12-16Not applicableEu
KinzalmonoTablet80 mgOralBayer Pharma Ag1998-12-16Not applicableEu
KinzalmonoTablet20 mgOralBayer Pharma Ag1998-12-16Not applicableEu
Mar-telmisartanTablet40 mgOralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Mar-telmisartanTablet80 mgOralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
MicardisTablet40 mgOralBoehringer Ingelheim International Gmb H1998-12-16Not applicableEu
MicardisTablet40 mgOralBoehringer Ingelheim International Gmb H1998-12-16Not applicableEu
MicardisTablet40 mg/1OralPhysicians Total Care, Inc.2005-01-19Not applicableUs
MicardisTablet20 mgOralBoehringer Ingelheim International Gmb H1998-12-16Not applicableEu
MicardisTablet80 mgOralBoehringer Ingelheim International Gmb H1998-12-16Not applicableEu
MicardisTablet40 mgOralBoehringer Ingelheim International Gmb H1998-12-16Not applicableEu
MicardisTablet80 mgOralBoehringer Ingelheim International Gmb H1998-12-16Not applicableEu
MicardisTablet40 mg/1OralBoehringer Ingelheim Pharmaceuticals, Inc.2000-12-01Not applicableUs
MicardisTablet80 mgOralBoehringer Ingelheim International Gmb H1998-12-16Not applicableEu
MicardisTablet80 mgOralBoehringer Ingelheim International Gmb H1998-12-16Not applicableEu
MicardisTablet80 mg/1OralPhysicians Total Care, Inc.2002-03-25Not applicableUs
MicardisTablet40 mgOralBoehringer Ingelheim International Gmb H1998-12-16Not applicableEu
MicardisTablet20 mgOralBoehringer Ingelheim International Gmb H1998-12-16Not applicableEu
MicardisTablet80 mg/1OralBoehringer Ingelheim Pharmaceuticals, Inc.2000-12-01Not applicableUs
MicardisTablet40 mgOralBoehringer Ingelheim International Gmb H1998-12-16Not applicableEu
MicardisTablet40 mgOralBoehringer Ingelheim International Gmb H1998-12-16Not applicableEu
MicardisTablet80 mgOralBoehringer Ingelheim International Gmb H1998-12-16Not applicableEu
MicardisTablet40 mgOralBoehringer Ingelheim International Gmb H1998-12-16Not applicableEu
MicardisTablet20 mg/1OralPhysicians Total Care, Inc.2010-11-02Not applicableUs
MicardisTablet80 mgOralBoehringer Ingelheim International Gmb H1998-12-16Not applicableEu
MicardisTablet20 mgOralBoehringer Ingelheim International Gmb H1998-12-16Not applicableEu
MicardisTablet80 mgOralBoehringer Ingelheim International Gmb H1998-12-16Not applicableEu
MicardisTablet80 mg/1OralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2012-03-15Not applicableUs
MicardisTablet40 mgOralBoehringer Ingelheim International Gmb H1998-12-16Not applicableEu
MicardisTablet80 mgOralBoehringer Ingelheim International Gmb H1998-12-16Not applicableEu
MicardisTablet80 mgOralBoehringer Ingelheim International Gmb H1998-12-16Not applicableEu
MicardisTablet40 mgOralBoehringer Ingelheim International Gmb H1998-12-16Not applicableEu
MicardisTablet20 mg/1OralBoehringer Ingelheim Pharmaceuticals, Inc.2000-12-01Not applicableUs
MicardisTablet20 mgOralBoehringer Ingelheim International Gmb H1998-12-16Not applicableEu
Micardis 40mg TabTablet40 mgOralBoehringer Ingelheim (Canada) Ltd Ltee1999-09-01Not applicableCanada
Micardis 80mg TabTablet80 mgOralBoehringer Ingelheim (Canada) Ltd Ltee1999-09-01Not applicableCanada
Mylan-telmisartanTablet40 mgOralMylan Pharmaceuticals Ulc2012-01-10Not applicableCanada
Mylan-telmisartanTablet80 mgOralMylan Pharmaceuticals Ulc2012-01-10Not applicableCanada
Ntp-telmisartanTablet80 mgOralTeva Canada LimitedNot applicableNot applicableCanada
Ntp-telmisartanTablet40 mgOralTeva Canada LimitedNot applicableNot applicableCanada
Pendo-telmisartanTablet40 mgOralPendopharm Division Of De Pharmascience IncNot applicableNot applicableCanada
Pendo-telmisartanTablet80 mgOralPendopharm Division Of De Pharmascience IncNot applicableNot applicableCanada
PMS-telmisartanTablet40 mgOralPharmascience Inc2012-08-28Not applicableCanada
PMS-telmisartanTablet80 mgOralPharmascience Inc2012-08-28Not applicableCanada
PritorTablet20 mgOralBayer Pharma Ag1998-12-11Not applicableEu
PritorTablet40 mgOralBayer Pharma Ag1998-12-11Not applicableEu
PritorTablet20 mgOralBayer Pharma Ag1998-12-11Not applicableEu
PritorTablet80 mgOralBayer Pharma Ag1998-12-11Not applicableEu
PritorTablet40 mgOralBayer Pharma Ag1998-12-11Not applicableEu
PritorTablet80 mgOralBayer Pharma Ag1998-12-11Not applicableEu
PritorTablet20 mgOralBayer Pharma Ag1998-12-11Not applicableEu
PritorTablet40 mgOralBayer Pharma Ag1998-12-11Not applicableEu
PritorTablet80 mgOralBayer Pharma Ag1998-12-11Not applicableEu
PritorTablet40 mgOralBayer Pharma Ag1998-12-11Not applicableEu
PritorTablet40 mgOralBayer Pharma Ag1998-12-11Not applicableEu
PritorTablet80 mgOralBayer Pharma Ag1998-12-11Not applicableEu
PritorTablet20 mgOralBayer Pharma Ag1998-12-11Not applicableEu
PritorTablet80 mgOralBayer Pharma Ag1998-12-11Not applicableEu
PritorTablet80 mgOralBayer Pharma Ag1998-12-11Not applicableEu
PritorTablet80 mgOralBayer Pharma Ag1998-12-11Not applicableEu
PritorTablet40 mgOralBayer Pharma Ag1998-12-11Not applicableEu
PritorTablet20 mgOralBayer Pharma Ag1998-12-11Not applicableEu
PritorTablet40 mgOralBayer Pharma Ag1998-12-11Not applicableEu
PritorTablet80 mgOralBayer Pharma Ag1998-12-11Not applicableEu
PritorTablet40 mgOralBayer Pharma Ag1998-12-11Not applicableEu
PritorTablet20 mgOralBayer Pharma Ag1998-12-11Not applicableEu
Ran-telmisartanTablet40 mgOralRanbaxy Pharmaceuticals Canada Inc.2013-06-14Not applicableCanada
Ran-telmisartanTablet80 mgOralRanbaxy Pharmaceuticals Canada Inc.2013-06-14Not applicableCanada
Sandoz TelmisartanTablet80 mgOralSandoz Canada Incorporated2012-01-04Not applicableCanada
Sandoz TelmisartanTablet40 mgOralSandoz Canada Incorporated2012-01-04Not applicableCanada
Septa-telmisartanTablet40 mgOralSepta Pharmaceuticals IncNot applicableNot applicableCanada
Septa-telmisartanTablet80 mgOralSepta Pharmaceuticals IncNot applicableNot applicableCanada
TelmisartanTablet20 mg/1OralRoxane Laboratories, Inc.2014-01-08Not applicableUs
TelmisartanTablet80 mgOralPharmascience Inc2015-02-12Not applicableCanada
TelmisartanTablet40 mgOralPro Doc Limitee2012-11-22Not applicableCanada
TelmisartanTablet80 mgOralSanis Health Inc2012-07-20Not applicableCanada
TelmisartanTablet40 mgOralPharmascience Inc2015-02-12Not applicableCanada
TelmisartanTablet40 mg/1OralRoxane Laboratories, Inc.2014-01-08Not applicableUs
TelmisartanTablet80 mgOralPro Doc Limitee2012-11-22Not applicableCanada
TelmisartanTablet40 mgOralSivem Pharmaceuticals Ulc2012-07-26Not applicableCanada
TelmisartanTablet80 mg/1OralRoxane Laboratories, Inc.2014-01-08Not applicableUs
TelmisartanTablet80 mgOralSivem Pharmaceuticals Ulc2012-07-26Not applicableCanada
TelmisartanTablet40 mgOralSanis Health Inc2012-07-20Not applicableCanada
Telmisartan TabletsTablet40 mgOralAccord Healthcare Inc2014-03-12Not applicableCanada
Telmisartan TabletsTablet80 mgOralAccord Healthcare Inc2014-03-12Not applicableCanada
Teva-telmisartanTablet40 mgOralTeva Canada Limited2012-01-09Not applicableCanada
Teva-telmisartanTablet80 mgOralTeva Canada Limited2012-01-09Not applicableCanada
Torrent-telmisartanTablet40 mgOralTorrent Pharmaceuticals LimitedNot applicableNot applicableCanada
Torrent-telmisartanTablet80 mgOralTorrent Pharmaceuticals LimitedNot applicableNot applicableCanada
Van-telmisartanTablet40 mgOralVanc Pharmaceuticals Inc2015-07-10Not applicableCanada
Van-telmisartanTablet80 mgOralVanc Pharmaceuticals Inc2015-07-10Not applicableCanada
Zinda-telmisartanTablet40 mgOralZinda Pharma LimitedNot applicableNot applicableCanada
Zinda-telmisartanTablet80 mgOralZinda Pharma LimitedNot applicableNot applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-telmisartanTablet40 mgOralApotex Inc2014-07-18Not applicableCanada
Apo-telmisartanTablet80 mgOralApotex Inc2014-07-18Not applicableCanada
TelmisartanTablet20 mg/1OralGlenmark Pharmaceuticals Inc., Usa2014-07-07Not applicableUs
TelmisartanTablet80 mg/1OralJubilant Cadista Pharmaceuticals Inc.2016-08-22Not applicableUs
TelmisartanTablet40 mg/1OralSandoz Inc2015-02-06Not applicableUs
TelmisartanTablet80 mg/1OralCadila Healthcare Limited2014-08-27Not applicableUs
TelmisartanTablet40 mg/1OralQualitest Pharmaceuticals2013-03-062017-02-28Us
TelmisartanTablet20 mg/1OralMylan Pharmaceuticals Inc.2014-07-07Not applicableUs
TelmisartanTablet80 mg/1OralTorrent Pharmaceuticals Limited2014-07-07Not applicableUs
TelmisartanTablet20 mg/1OralAscend Laboratories, LLC2016-06-12Not applicableUs
TelmisartanTablet80 mg/1OralCamber Pharmaceuticals, Inc.2016-04-25Not applicableUs
TelmisartanTablet40 mg/1OralActavis Pharma, Inc.2014-01-08Not applicableUs
TelmisartanTablet20 mg/1OralZydus Pharmaceuticals (USA) Inc.2014-08-27Not applicableUs
TelmisartanTablet40 mg/1OralGlenmark Pharmaceuticals Inc., Usa2014-07-07Not applicableUs
TelmisartanTablet20 mg/1OralAlembic Pharmaceuticals Inc.2016-06-25Not applicableUs
TelmisartanTablet80 mg/1OralSandoz Inc2015-02-06Not applicableUs
TelmisartanTablet20 mg/1OralAurobindo Pharma Limited2015-09-03Not applicableUs
TelmisartanTablet80 mg/1OralQualitest Pharmaceuticals2013-03-062017-03-31Us
TelmisartanTablet40 mg/1OralMylan Pharmaceuticals Inc.2014-07-07Not applicableUs
TelmisartanTablet40 mg/1OralAscend Laboratories, LLC2016-06-12Not applicableUs
TelmisartanTablet20 mg/1OralMedsource Pharmaceuticals2014-08-27Not applicableUs
TelmisartanTablet40 mg/1OralZydus Pharmaceuticals (USA) Inc.2014-08-27Not applicableUs
TelmisartanTablet20 mg/1OralJubilant Cadista Pharmaceuticals Inc.2016-08-22Not applicableUs
TelmisartanTablet80 mg/1OralActavis Pharma, Inc.2014-01-08Not applicableUs
TelmisartanTablet80 mg/1OralGlenmark Pharmaceuticals Inc., Usa2014-07-07Not applicableUs
TelmisartanTablet40 mg/1OralAlembic Pharmaceuticals Inc.2016-06-25Not applicableUs
TelmisartanTablet20 mg/1OralTorrent Pharmaceuticals Limited2014-07-07Not applicableUs
TelmisartanTablet40 mg/1OralAurobindo Pharma Limited2015-09-03Not applicableUs
TelmisartanTablet20 mg/1OralCamber Pharmaceuticals, Inc.2016-04-25Not applicableUs
TelmisartanTablet80 mg/1OralMylan Pharmaceuticals Inc.2014-07-07Not applicableUs
TelmisartanTablet80 mg/1OralAscend Laboratories, LLC2016-06-12Not applicableUs
TelmisartanTablet20 mg/1OralCadila Healthcare Limited2014-08-27Not applicableUs
TelmisartanTablet80 mg/1OralZydus Pharmaceuticals (USA) Inc.2014-08-27Not applicableUs
TelmisartanTablet40 mg/1OralJubilant Cadista Pharmaceuticals Inc.2016-08-22Not applicableUs
TelmisartanTablet20 mg/1OralSandoz Inc2015-02-06Not applicableUs
TelmisartanTablet40 mg/1OralAvera Mc Kennan Hospital2015-04-15Not applicableUs
TelmisartanTablet80 mg/1OralAlembic Pharmaceuticals Inc.2016-06-25Not applicableUs
TelmisartanTablet40 mg/1OralTorrent Pharmaceuticals Limited2014-07-07Not applicableUs
TelmisartanTablet20 mg/1OralActavis Pharma, Inc.2014-01-08Not applicableUs
TelmisartanTablet80 mg/1OralAurobindo Pharma Limited2015-09-03Not applicableUs
TelmisartanTablet40 mg/1OralCamber Pharmaceuticals, Inc.2016-04-25Not applicableUs
TelmisartanTablet20 mg/1OralQualitest Pharmaceuticals2013-03-062017-02-28Us
TelmisartanTablet40 mg/1OralCadila Healthcare Limited2014-08-27Not applicableUs
Telmisartan TevaTablet80 mgOralTeva B.V.2010-01-26Not applicableEu
Telmisartan TevaTablet80 mgOralTeva B.V.2010-01-26Not applicableEu
Telmisartan TevaTablet20 mgOralTeva B.V.2010-01-26Not applicableEu
Telmisartan TevaTablet20 mgOralTeva B.V.2010-01-26Not applicableEu
Telmisartan TevaTablet40 mgOralTeva B.V.2010-01-26Not applicableEu
Telmisartan TevaTablet40 mgOralTeva B.V.2010-01-26Not applicableEu
Telmisartan TevaTablet20 mgOralTeva B.V.2010-01-26Not applicableEu
Telmisartan TevaTablet20 mgOralTeva B.V.2010-01-26Not applicableEu
Telmisartan TevaTablet80 mgOralTeva B.V.2010-01-26Not applicableEu
Telmisartan TevaTablet80 mgOralTeva B.V.2010-01-26Not applicableEu
Telmisartan TevaTablet40 mgOralTeva B.V.2010-01-26Not applicableEu
Telmisartan TevaTablet40 mgOralTeva B.V.2010-01-26Not applicableEu
Telmisartan TevaTablet80 mgOralTeva B.V.2010-01-26Not applicableEu
Telmisartan TevaTablet80 mgOralTeva B.V.2010-01-26Not applicableEu
Telmisartan TevaTablet20 mgOralTeva B.V.2010-01-26Not applicableEu
Telmisartan TevaTablet20 mgOralTeva B.V.2010-01-26Not applicableEu
Telmisartan TevaTablet40 mgOralTeva B.V.2010-01-26Not applicableEu
Telmisartan TevaTablet80 mgOralTeva B.V.2010-01-26Not applicableEu
Telmisartan TevaTablet80 mgOralTeva B.V.2010-01-26Not applicableEu
Telmisartan TevaTablet40 mgOralTeva B.V.2010-01-26Not applicableEu
Telmisartan TevaTablet20 mgOralTeva B.V.2010-01-26Not applicableEu
Telmisartan TevaTablet20 mgOralTeva B.V.2010-01-26Not applicableEu
Telmisartan TevaTablet40 mgOralTeva B.V.2010-01-26Not applicableEu
Telmisartan TevaTablet40 mgOralTeva B.V.2010-01-26Not applicableEu
Telmisartan TevaTablet80 mgOralTeva B.V.2010-01-26Not applicableEu
Telmisartan TevaTablet80 mgOralTeva B.V.2010-01-26Not applicableEu
Telmisartan TevaTablet40 mgOralTeva B.V.2010-01-26Not applicableEu
Telmisartan TevaTablet40 mgOralTeva B.V.2010-01-26Not applicableEu
Telmisartan TevaTablet80 mgOralTeva B.V.2010-01-26Not applicableEu
Telmisartan TevaTablet80 mgOralTeva B.V.2010-01-26Not applicableEu
Telmisartan TevaTablet20 mgOralTeva B.V.2010-01-26Not applicableEu
Telmisartan TevaTablet20 mgOralTeva B.V.2010-01-26Not applicableEu
Telmisartan TevaTablet80 mgOralTeva B.V.2010-01-26Not applicableEu
Telmisartan TevaTablet80 mgOralTeva B.V.2010-01-26Not applicableEu
Telmisartan TevaTablet40 mgOralTeva B.V.2010-01-26Not applicableEu
Telmisartan TevaTablet40 mgOralTeva B.V.2010-01-26Not applicableEu
Telmisartan TevaTablet40 mgOralTeva B.V.2010-01-26Not applicableEu
Telmisartan TevaTablet40 mgOralTeva B.V.2010-01-26Not applicableEu
Telmisartan TevaTablet20 mgOralTeva B.V.2010-01-26Not applicableEu
Telmisartan TevaTablet20 mgOralTeva B.V.2010-01-26Not applicableEu
Telmisartan TevaTablet20 mgOralTeva B.V.2010-01-26Not applicableEu
Telmisartan TevaTablet40 mgOralTeva B.V.2010-01-26Not applicableEu
Telmisartan TevaTablet20 mgOralTeva B.V.2010-01-26Not applicableEu
Telmisartan TevaTablet40 mgOralTeva B.V.2010-01-26Not applicableEu
Telmisartan TevaTablet40 mgOralTeva B.V.2010-01-26Not applicableEu
Telmisartan TevaTablet80 mgOralTeva B.V.2010-01-26Not applicableEu
Telmisartan TevaTablet80 mgOralTeva B.V.2010-01-26Not applicableEu
Telmisartan TevaTablet20 mgOralTeva B.V.2010-01-26Not applicableEu
Telmisartan TevaTablet20 mgOralTeva B.V.2010-01-26Not applicableEu
Telmisartan TevaTablet80 mgOralTeva B.V.2010-01-26Not applicableEu
Telmisartan TevaTablet80 mgOralTeva B.V.2010-01-26Not applicableEu
Telmisartan TevaTablet40 mgOralTeva B.V.2010-01-26Not applicableEu
Telmisartan TevaTablet40 mgOralTeva B.V.2010-01-26Not applicableEu
Telmisartan TevaTablet80 mgOralTeva B.V.2010-01-26Not applicableEu
Telmisartan TevaTablet80 mgOralTeva B.V.2010-01-26Not applicableEu
Telmisartan TevaTablet20 mgOralTeva B.V.2010-01-26Not applicableEu
Telmisartan TevaTablet20 mgOralTeva B.V.2010-01-26Not applicableEu
Telmisartan TevaTablet20 mgOralTeva B.V.2010-01-26Not applicableEu
Telmisartan TevaTablet80 mgOralTeva B.V.2010-01-26Not applicableEu
Telmisartan TevaTablet20 mgOralTeva B.V.2010-01-26Not applicableEu
Telmisartan TevaTablet40 mgOralTeva B.V.2010-01-26Not applicableEu
Telmisartan TevaTablet40 mgOralTeva B.V.2010-01-26Not applicableEu
Telmisartan Teva PharmaTablet40 mgOralTeva B.V.2011-10-03Not applicableEu
Telmisartan Teva PharmaTablet40 mgOralTeva B.V.2011-10-03Not applicableEu
Telmisartan Teva PharmaTablet80 mgOralTeva B.V.2011-10-03Not applicableEu
Telmisartan Teva PharmaTablet20 mgOralTeva B.V.2011-10-03Not applicableEu
Telmisartan Teva PharmaTablet20 mgOralTeva B.V.2011-10-03Not applicableEu
Telmisartan Teva PharmaTablet40 mgOralTeva B.V.2011-10-03Not applicableEu
Telmisartan Teva PharmaTablet80 mgOralTeva B.V.2011-10-03Not applicableEu
Telmisartan Teva PharmaTablet40 mgOralTeva B.V.2011-10-03Not applicableEu
Telmisartan Teva PharmaTablet20 mgOralTeva B.V.2011-10-03Not applicableEu
Telmisartan Teva PharmaTablet20 mgOralTeva B.V.2011-10-03Not applicableEu
Telmisartan Teva PharmaTablet40 mgOralTeva B.V.2011-10-03Not applicableEu
Telmisartan Teva PharmaTablet80 mgOralTeva B.V.2011-10-03Not applicableEu
Telmisartan Teva PharmaTablet80 mgOralTeva B.V.2011-10-03Not applicableEu
Telmisartan Teva PharmaTablet20 mgOralTeva B.V.2011-10-03Not applicableEu
Telmisartan Teva PharmaTablet20 mgOralTeva B.V.2011-10-03Not applicableEu
Telmisartan Teva PharmaTablet40 mgOralTeva B.V.2011-10-03Not applicableEu
Telmisartan Teva PharmaTablet80 mgOralTeva B.V.2011-10-03Not applicableEu
Telmisartan Teva PharmaTablet80 mgOralTeva B.V.2011-10-03Not applicableEu
Telmisartan Teva PharmaTablet40 mgOralTeva B.V.2011-10-03Not applicableEu
Telmisartan Teva PharmaTablet40 mgOralTeva B.V.2011-10-03Not applicableEu
Telmisartan Teva PharmaTablet80 mgOralTeva B.V.2011-10-03Not applicableEu
Telmisartan Teva PharmaTablet20 mgOralTeva B.V.2011-10-03Not applicableEu
Telmisartan Teva PharmaTablet20 mgOralTeva B.V.2011-10-03Not applicableEu
Telmisartan Teva PharmaTablet20 mgOralTeva B.V.2011-10-03Not applicableEu
Telmisartan Teva PharmaTablet40 mgOralTeva B.V.2011-10-03Not applicableEu
Telmisartan Teva PharmaTablet80 mgOralTeva B.V.2011-10-03Not applicableEu
Telmisartan Teva PharmaTablet80 mgOralTeva B.V.2011-10-03Not applicableEu
Telmisartan Teva PharmaTablet20 mgOralTeva B.V.2011-10-03Not applicableEu
Telmisartan Teva PharmaTablet40 mgOralTeva B.V.2011-10-03Not applicableEu
Telmisartan Teva PharmaTablet80 mgOralTeva B.V.2011-10-03Not applicableEu
Telmisartan Teva PharmaTablet80 mgOralTeva B.V.2011-10-03Not applicableEu
Telmisartan Teva PharmaTablet20 mgOralTeva B.V.2011-10-03Not applicableEu
Telmisartan Teva PharmaTablet40 mgOralTeva B.V.2011-10-03Not applicableEu
Telmisartan Teva PharmaTablet40 mgOralTeva B.V.2011-10-03Not applicableEu
Telmisartan Teva PharmaTablet80 mgOralTeva B.V.2011-10-03Not applicableEu
Telmisartan Teva PharmaTablet20 mgOralTeva B.V.2011-10-03Not applicableEu
Telmisartan Teva PharmaTablet40 mgOralTeva B.V.2011-10-03Not applicableEu
Telmisartan Teva PharmaTablet40 mgOralTeva B.V.2011-10-03Not applicableEu
Telmisartan Teva PharmaTablet80 mgOralTeva B.V.2011-10-03Not applicableEu
Telmisartan Teva PharmaTablet20 mgOralTeva B.V.2011-10-03Not applicableEu
Telmisartan Teva PharmaTablet20 mgOralTeva B.V.2011-10-03Not applicableEu
Telmisartan Teva PharmaTablet40 mgOralTeva B.V.2011-10-03Not applicableEu
Telmisartan Teva PharmaTablet80 mgOralTeva B.V.2011-10-03Not applicableEu
Telmisartan Teva PharmaTablet20 mgOralTeva B.V.2011-10-03Not applicableEu
Telmisartan Teva PharmaTablet20 mgOralTeva B.V.2011-10-03Not applicableEu
Telmisartan Teva PharmaTablet40 mgOralTeva B.V.2011-10-03Not applicableEu
Telmisartan Teva PharmaTablet80 mgOralTeva B.V.2011-10-03Not applicableEu
Telmisartan Teva PharmaTablet80 mgOralTeva B.V.2011-10-03Not applicableEu
Telmisartan Teva PharmaTablet80 mgOralTeva B.V.2011-10-03Not applicableEu
Telmisartan Teva PharmaTablet20 mgOralTeva B.V.2011-10-03Not applicableEu
Telmisartan Teva PharmaTablet40 mgOralTeva B.V.2011-10-03Not applicableEu
Telmisartan Teva PharmaTablet40 mgOralTeva B.V.2011-10-03Not applicableEu
Telmisartan Teva PharmaTablet20 mgOralTeva B.V.2011-10-03Not applicableEu
Telmisartan Teva PharmaTablet40 mgOralTeva B.V.2011-10-03Not applicableEu
Telmisartan Teva PharmaTablet80 mgOralTeva B.V.2011-10-03Not applicableEu
Telmisartan Teva PharmaTablet80 mgOralTeva B.V.2011-10-03Not applicableEu
Telmisartan Teva PharmaTablet20 mgOralTeva B.V.2011-10-03Not applicableEu
Telmisartan Teva PharmaTablet20 mgOralTeva B.V.2011-10-03Not applicableEu
Telmisartan Teva PharmaTablet40 mgOralTeva B.V.2011-10-03Not applicableEu
Telmisartan Teva PharmaTablet80 mgOralTeva B.V.2011-10-03Not applicableEu
Telmisartan Teva PharmaTablet40 mgOralTeva B.V.2011-10-03Not applicableEu
Telmisartan Teva PharmaTablet80 mgOralTeva B.V.2011-10-03Not applicableEu
Telmisartan Teva PharmaTablet80 mgOralTeva B.V.2011-10-03Not applicableEu
Telmisartan Teva PharmaTablet20 mgOralTeva B.V.2011-10-03Not applicableEu
Telmisartan Teva PharmaTablet40 mgOralTeva B.V.2011-10-03Not applicableEu
ToluraTablet20 mgOralKrka, D.D., Novo Mesto  2010-06-04Not applicableEu
ToluraTablet80 mgOralKrka, D.D., Novo Mesto  2010-06-04Not applicableEu
ToluraTablet40 mgOralKrka, D.D., Novo Mesto  2010-06-04Not applicableEu
ToluraTablet20 mgOralKrka, D.D., Novo Mesto  2010-06-04Not applicableEu
ToluraTablet20 mgOralKrka, D.D., Novo Mesto  2010-06-04Not applicableEu
ToluraTablet80 mgOralKrka, D.D., Novo Mesto  2010-06-04Not applicableEu
ToluraTablet20 mgOralKrka, D.D., Novo Mesto  2010-06-04Not applicableEu
ToluraTablet80 mgOralKrka, D.D., Novo Mesto  2010-06-04Not applicableEu
ToluraTablet40 mgOralKrka, D.D., Novo Mesto  2010-06-04Not applicableEu
ToluraTablet40 mgOralKrka, D.D., Novo Mesto  2010-06-04Not applicableEu
ToluraTablet40 mgOralKrka, D.D., Novo Mesto  2010-06-04Not applicableEu
ToluraTablet20 mgOralKrka, D.D., Novo Mesto  2010-06-04Not applicableEu
ToluraTablet80 mgOralKrka, D.D., Novo Mesto  2010-06-04Not applicableEu
ToluraTablet20 mgOralKrka, D.D., Novo Mesto  2010-06-04Not applicableEu
ToluraTablet80 mgOralKrka, D.D., Novo Mesto  2010-06-04Not applicableEu
ToluraTablet40 mgOralKrka, D.D., Novo Mesto  2010-06-04Not applicableEu
ToluraTablet40 mgOralKrka, D.D., Novo Mesto  2010-06-04Not applicableEu
ToluraTablet80 mgOralKrka, D.D., Novo Mesto  2010-06-04Not applicableEu
ToluraTablet20 mgOralKrka, D.D., Novo Mesto  2010-06-04Not applicableEu
ToluraTablet80 mgOralKrka, D.D., Novo Mesto  2010-06-04Not applicableEu
ToluraTablet20 mgOralKrka, D.D., Novo Mesto  2010-06-04Not applicableEu
ToluraTablet80 mgOralKrka, D.D., Novo Mesto  2010-06-04Not applicableEu
ToluraTablet40 mgOralKrka, D.D., Novo Mesto  2010-06-04Not applicableEu
ToluraTablet40 mgOralKrka, D.D., Novo Mesto  2010-06-04Not applicableEu
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
PritorNot Available
Brand mixtures
NameLabellerIngredients
Ach-telmisartan HctzAccord Healthcare Inc
Act Telmisartan/hctActavis Pharma Company
Actelsar HctActavis Group Hf
Apo-telmisartan/hctzApotex Inc
Auro-telmisartan HctzAuro Pharma Inc
Micardis HctBoehringer Ingelheim Pharmaceuticals, Inc.
Micardis PlusBoehringer Ingelheim (Canada) Ltd Ltee
Mylan-telmisartan HctzMylan Pharmaceuticals Ulc
Ntp-telmisartan HctzTeva Canada Limited
Pendo-telmisartan-hctzPendopharm Division Of De Pharmascience Inc
PMS-telmisartan-hctzPharmascience Inc
Ran-telmisartan HctzRanbaxy Pharmaceuticals Canada Inc.
Sandoz Telmisartan HctSandoz Canada Incorporated
Telmisartan and AmlodipineMylan Pharmaceuticals Inc.
Telmisartan and HydrochlorothiazideRoxane Laboratories, Inc.
Telmisartan and Hydrochlorothiazide 40 Mg/12.5 mgAlembic Pharmaceuticals Limited
Telmisartan and Hydrochlorothiazide 80 Mg/12.5 mgAlembic Pharmaceuticals Limited
Telmisartan and Hydrochlorothiazide 80 Mg/25 mgAlembic Pharmaceuticals Limited
Telmisartan and HydrochlorthiazideTorrent Pharmaceuticals Limited
Telmisartan HctzSivem Pharmaceuticals Ulc
Telmisartan-hctzPro Doc Limitee
Telmisartan/hctzSanis Health Inc
Teva-telmisartan HctzTeva Canada Limited
Torrent-telmisartan and HydrochlorothiazideTorrent Pharmaceuticals Limited
TwynstaBoehringer Ingelheim Pharmaceuticals, Inc.
Van-telmisartan-hctzVanc Pharmaceuticals Inc
Zinda-telmisartan/ HctzZinda Pharma Limited
SaltsNot Available
Categories
UNIIU5SYW473RQ
CAS number144701-48-4
WeightAverage: 514.6169
Monoisotopic: 514.236876224
Chemical FormulaC33H30N4O2
InChI KeyRMMXLENWKUUMAY-UHFFFAOYSA-N
InChI
InChI=1S/C33H30N4O2/c1-4-9-30-35-31-21(2)18-24(32-34-27-12-7-8-13-28(27)36(32)3)19-29(31)37(30)20-22-14-16-23(17-15-22)25-10-5-6-11-26(25)33(38)39/h5-8,10-19H,4,9,20H2,1-3H3,(H,38,39)
IUPAC Name
2-(4-{[4-methyl-6-(1-methyl-1H-1,3-benzodiazol-2-yl)-2-propyl-1H-1,3-benzodiazol-1-yl]methyl}phenyl)benzoic acid
SMILES
CCCC1=NC2=C(C=C(C=C2C)C2=NC3=CC=CC=C3N2C)N1CC1=CC=C(C=C1)C1=CC=CC=C1C(O)=O
Pharmacology
IndicationUsed alone or in combination with other classes of antihypertensives for the treatment of hypertension. Also used in the treatment of diabetic nephropathy in hypertensive patients with type 2 diabetes mellitus, as well as the treatment of congestive heart failure (only in patients who cannot tolerate ACE inhibitors).
Structured Indications
PharmacodynamicsTelmisartan is an orally active nonpeptide angiotensin II antagonist that acts on the AT1 receptor subtype. It has the highest affinity for the AT1 receptor among commercially available ARBS and has minimal affinity for the AT2 receptor. New studies suggest that telmisartan may also have PPARγ agonistic properties that could potentially confer beneficial metabolic effects, as PPARγ is a nuclear receptor that regulates specific gene transcription, and whose target genes are involved in the regulation of glucose and lipid metabolism, as well as anti-inflammatory responses. This observation is currently being explored in clinical trials. Angiotensin II is formed from angiotensin I in a reaction catalyzed by angiotensin-converting enzyme (ACE, kininase II). Angiotensin II is the principal pressor agent of the renin-angiotensin system, with effects that include vasoconstriction, stimulation of synthesis and release of aldosterone, cardiac stimulation, and renal reabsorption of sodium. Telmisartan works by blocking the vasoconstrictor and aldosterone secretory effects of angiotensin II.
Mechanism of actionTelmisartan interferes with the binding of angiotensin II to the angiotensin II AT1-receptor by binding reversibly and selectively to the receptors in vascular smooth muscle and the adrenal gland. As angiotensin II is a vasoconstrictor, which also stimulates the synthesis and release of aldosterone, blockage of its effects results in decreases in systemic vascular resistance. Telmisartan does not inhibit the angiotensin converting enzyme, other hormone receptors, or ion channels. Studies also suggest that telmisartan is a partial agonist of PPARγ, which is an established target for antidiabetic drugs. This suggests that telmisartan can improve carbohydrate and lipid metabolism, as well as control insulin resistance without causing the side effects that are associated with full PPARγ activators.
TargetKindPharmacological actionActionsOrganismUniProt ID
Type-1 angiotensin II receptorProteinyes
antagonist
HumanP30556 details
Peroxisome proliferator-activated receptor gammaProteinyes
partial agonist
HumanP37231 details
Related Articles
AbsorptionAbsolute bioavailability depends on dosage. Food slightly decreases the bioavailability (a decrease of about 6% is seen when the 40-mg dose is administered with food).
Volume of distribution
  • 500 L
Protein bindingHighly bound to plasma proteins (>99.5%), mainly albumin and a1-acid glycoprotein. Binding is not dose-dependent.
Metabolism

Minimally metabolized by conjugation to form a pharmacologically inactive acylglucuronide; the glucuronide of the parent compound is the only metabolite that has been identified in human plasma and urine. The cytochrome P450 isoenzymes are not involved in the metabolism of telmisartan.

Route of eliminationFollowing either intravenous or oral administration of 14C-labeled telmisartan, most of the administered dose (>97%) was eliminated unchanged in feces via biliary excretion; only minute amounts were found in the urine (0.91% and 0.49% of total radioactivity, respectively).
Half lifeBi-exponential decay kinetics with a terminal elimination half-life of approximately 24 hours.
Clearance
  • >800 mL/min
ToxicityIntravenous LD50 in rats is 150-200 mg/kg in males and 200 to 250 mg/kg in females. Acute oral toxicity is low: no deaths and no changes occurred in rats or dogs at 2000 mg/kg, the highest dose tested. Limited data are available with regard to overdosage in humans. The most likely manifestations of overdosage with telmisartan would be hypotension, dizziness and tachycardia; bradycardia could occur from parasympathetic (vagal) stimulation.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Telmisartan Action PathwayDrug actionSMP00164
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Telmisartan.Experimental
AcebutololThe risk or severity of adverse effects can be increased when Telmisartan is combined with Acebutolol.Approved
AceclofenacThe risk or severity of adverse effects can be increased when Telmisartan is combined with Aceclofenac.Approved
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Telmisartan.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Telmisartan is combined with Acetazolamide.Approved, Vet Approved
AcetovanilloneThe risk or severity of adverse effects can be increased when Telmisartan is combined with Acetovanillone.Investigational
AcetyldigitoxinThe serum concentration of Acetyldigitoxin can be increased when it is combined with Telmisartan.Approved
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Telmisartan.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Telmisartan is combined with Adapalene.Approved
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Telmisartan.Approved
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Telmisartan.Approved
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Telmisartan.Experimental
AlfuzosinAlfuzosin may increase the hypotensive activities of Telmisartan.Approved, Investigational
AliskirenAliskiren may increase the hyperkalemic activities of Telmisartan.Approved, Investigational
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Telmisartan.Approved, Investigational
AlprenololAlprenolol may increase the hypotensive activities of Telmisartan.Approved, Withdrawn
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Telmisartan.Approved, Investigational
AmifostineTelmisartan may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Telmisartan.Approved
AmiodaroneThe risk or severity of adverse effects can be increased when Telmisartan is combined with Amiodarone.Approved, Investigational
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Telmisartan.Approved
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Telmisartan.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Telmisartan.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Telmisartan is combined with Amphotericin B.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Telmisartan is combined with Amyl Nitrite.Approved
AnisodamineThe risk or severity of adverse effects can be increased when Telmisartan is combined with Anisodamine.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Telmisartan is combined with Antipyrine.Approved
AnvirzelThe serum concentration of Anvirzel can be increased when it is combined with Telmisartan.Investigational
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Telmisartan.Approved
ApomorphineThe risk or severity of adverse effects can be increased when Telmisartan is combined with Apomorphine.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Apraclonidine is combined with Telmisartan.Approved
ApremilastThe risk or severity of adverse effects can be increased when Telmisartan is combined with Apremilast.Approved, Investigational
ArdeparinArdeparin may increase the hyperkalemic activities of Telmisartan.Approved, Withdrawn
AripiprazoleAripiprazole may increase the hypotensive activities of Telmisartan.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Telmisartan is combined with Arotinolol.Approved
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Telmisartan.Approved, Investigational
AtazanavirThe serum concentration of Atazanavir can be increased when it is combined with Telmisartan.Approved, Investigational
AtenololThe risk or severity of adverse effects can be increased when Atenolol is combined with Telmisartan.Approved
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Telmisartan.Approved, Investigational
AzapropazoneThe risk or severity of adverse effects can be increased when Telmisartan is combined with Azapropazone.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Telmisartan is combined with Azelastine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Telmisartan is combined with Azilsartan medoxomil.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Telmisartan is combined with Balsalazide.Approved, Investigational
BarbexacloneBarbexaclone may increase the hypotensive activities of Telmisartan.Experimental
BarbitalBarbital may increase the hypotensive activities of Telmisartan.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Telmisartan is combined with Barnidipine.Approved
BemiparinBemiparin may increase the hyperkalemic activities of Telmisartan.Approved
BenazeprilThe risk or severity of adverse effects can be increased when Telmisartan is combined with Benazepril.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Telmisartan.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Telmisartan.Withdrawn
BenoxaprofenThe risk or severity of adverse effects can be increased when Telmisartan is combined with Benoxaprofen.Withdrawn
BepridilTelmisartan may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Telmisartan.Approved, Vet Approved
BetaxololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Telmisartan.Approved
BethanidineBethanidine may increase the hypotensive activities of Telmisartan.Approved
Betulinic AcidThe risk or severity of adverse effects can be increased when Telmisartan is combined with Betulinic Acid.Investigational
BimatoprostBimatoprost may increase the hypotensive activities of Telmisartan.Approved, Investigational
BisoprololThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Telmisartan.Approved
BoceprevirThe serum concentration of Boceprevir can be increased when it is combined with Telmisartan.Approved
BortezomibThe risk or severity of adverse effects can be increased when Telmisartan is combined with Bortezomib.Approved, Investigational
BosentanBosentan may increase the hypotensive activities of Telmisartan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Telmisartan.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Telmisartan.Approved
BretyliumThe risk or severity of adverse effects can be increased when Telmisartan is combined with Bretylium.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Telmisartan.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Telmisartan.Approved
BromfenacThe risk or severity of adverse effects can be increased when Telmisartan is combined with Bromfenac.Approved
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Telmisartan.Approved, Investigational
BucillamineThe risk or severity of adverse effects can be increased when Telmisartan is combined with Bucillamine.Investigational
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Telmisartan.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Telmisartan is combined with Bupivacaine.Approved, Investigational
BupranololTelmisartan may increase the hypotensive activities of Bupranolol.Approved
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Telmisartan.Approved
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Telmisartan.Approved
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Telmisartan.Experimental
CanagliflozinCanagliflozin may increase the hyperkalemic activities of Telmisartan.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Telmisartan.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Telmisartan is combined with Candoxatril.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Telmisartan is combined with Captopril.Approved
CarbamazepineThe serum concentration of Carbamazepine can be increased when it is combined with Telmisartan.Approved, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Telmisartan is combined with Carbetocin.Approved
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Telmisartan.Approved
CaroxazoneCaroxazone may increase the hypotensive activities of Telmisartan.Withdrawn
CarprofenThe risk or severity of adverse effects can be increased when Telmisartan is combined with Carprofen.Approved, Vet Approved, Withdrawn
CarteololThe risk or severity of adverse effects can be increased when Carteolol is combined with Telmisartan.Approved
CarvedilolThe risk or severity of adverse effects can be increased when Telmisartan is combined with Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Telmisartan is combined with Castanospermine.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Telmisartan is combined with Celecoxib.Approved, Investigational
CeliprololTelmisartan may increase the hypotensive activities of Celiprolol.Approved, Investigational
CeritinibThe serum concentration of Ceritinib can be increased when it is combined with Telmisartan.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Telmisartan.Withdrawn
CertoparinCertoparin may increase the hyperkalemic activities of Telmisartan.Approved
ChloroquineThe risk or severity of adverse effects can be increased when Telmisartan is combined with Chloroquine.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Telmisartan.Approved, Vet Approved
ChlorpromazineThe serum concentration of Chlorpromazine can be increased when it is combined with Telmisartan.Approved, Vet Approved
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Telmisartan.Approved
CilazaprilThe risk or severity of adverse effects can be increased when Telmisartan is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Telmisartan is combined with Cilnidipine.Approved
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Telmisartan.Approved
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Telmisartan.Approved
CiprofloxacinThe serum concentration of Ciprofloxacin can be increased when it is combined with Telmisartan.Approved, Investigational
CiprofloxacinTelmisartan may increase the arrhythmogenic activities of Ciprofloxacin.Approved, Investigational
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Telmisartan.Approved
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Telmisartan.Approved
ClarithromycinThe serum concentration of Clarithromycin can be increased when it is combined with Telmisartan.Approved
ClevidipineThe risk or severity of adverse effects can be increased when Telmisartan is combined with Clevidipine.Approved
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Telmisartan.Approved, Illicit
ClofarabineThe risk or severity of adverse effects can be increased when Telmisartan is combined with Clofarabine.Approved, Investigational
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Telmisartan.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Telmisartan is combined with Clomipramine.Approved, Vet Approved
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Telmisartan.Approved
ClonixinThe risk or severity of adverse effects can be increased when Telmisartan is combined with Clonixin.Approved
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Telmisartan.Approved, Nutraceutical
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Telmisartan.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Telmisartan.Approved
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Telmisartan.Approved
ConivaptanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Conivaptan.Approved, Investigational
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Telmisartan.Approved
CrizotinibThe serum concentration of Crizotinib can be increased when it is combined with Telmisartan.Approved
CryptenamineCryptenamine may increase the hypotensive activities of Telmisartan.Approved
CurcuminThe risk or severity of adverse effects can be increased when Telmisartan is combined with Curcumin.Investigational
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Telmisartan.Approved, Investigational, Vet Approved
CyclosporineTelmisartan may increase the hyperkalemic activities of Cyclosporine.Approved, Investigational, Vet Approved
CyclothiazideCyclothiazide may increase the hypotensive activities of Telmisartan.Approved
D-LimoneneThe risk or severity of adverse effects can be increased when Telmisartan is combined with D-Limonene.Investigational
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Telmisartan.Approved
DabrafenibThe serum concentration of Dabrafenib can be increased when it is combined with Telmisartan.Approved
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Telmisartan.Approved
DalteparinDalteparin may increase the hyperkalemic activities of Telmisartan.Approved
DapagliflozinThe risk or severity of adverse effects can be increased when Telmisartan is combined with Dapagliflozin.Approved
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Telmisartan.Investigational
DasatinibThe serum concentration of Dasatinib can be increased when it is combined with Telmisartan.Approved, Investigational
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Telmisartan.Approved
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Telmisartan.Approved
DeserpidineTelmisartan may increase the hypotensive activities of Deserpidine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Telmisartan is combined with Desflurane.Approved
DeslanosideThe serum concentration of Deslanoside can be increased when it is combined with Telmisartan.Approved
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Telmisartan.Approved, Investigational, Vet Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Telmisartan.Approved, Vet Approved
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Telmisartan.Approved, Illicit, Vet Approved
DiazoxideDiazoxide may increase the hypotensive activities of Telmisartan.Approved
DiclofenacThe risk or severity of adverse effects can be increased when Telmisartan is combined with Diclofenac.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Telmisartan is combined with Diclofenamide.Approved
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Telmisartan.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Telmisartan is combined with Diflunisal.Approved
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Telmisartan.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Telmisartan.Approved
DihydralazineTelmisartan may increase the hypotensive activities of Dihydralazine.Investigational
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Telmisartan.Illicit
DiltiazemThe risk or severity of adverse effects can be increased when Diltiazem is combined with Telmisartan.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Telmisartan is combined with Dinutuximab.Approved
DipyridamoleThe risk or severity of adverse effects can be increased when Telmisartan is combined with Dipyridamole.Approved
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Telmisartan.Approved, Investigational
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Telmisartan.Approved, Investigational, Vet Approved
DorzolamideDorzolamide may increase the hypotensive activities of Telmisartan.Approved
DoxazosinThe risk or severity of adverse effects can be increased when Doxazosin is combined with Telmisartan.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Telmisartan.Approved, Investigational
DrospirenoneTelmisartan may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Telmisartan is combined with Droxicam.Approved
DuloxetineTelmisartan may increase the orthostatic hypotensive activities of Duloxetine.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Telmisartan is combined with Duvelisib.Investigational
E6201The risk or severity of adverse effects can be increased when Telmisartan is combined with E6201.Investigational
EbselenThe risk or severity of adverse effects can be increased when Telmisartan is combined with Ebselen.Investigational
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Telmisartan.Approved
EfonidipineTelmisartan may increase the hypotensive activities of Efonidipine.Approved
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Telmisartan.Approved, Investigational
EmpagliflozinThe risk or severity of adverse effects can be increased when Telmisartan is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Telmisartan is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Telmisartan is combined with Enalaprilat.Approved
EnoxaparinEnoxaparin may increase the hyperkalemic activities of Telmisartan.Approved
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Telmisartan.Approved, Investigational
EpirizoleThe risk or severity of adverse effects can be increased when Telmisartan is combined with Epirizole.Approved
EplerenoneEplerenone may increase the hyperkalemic activities of Telmisartan.Approved
EpoprostenolTelmisartan may increase the hypotensive activities of Epoprostenol.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Telmisartan.Approved
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Telmisartan.Approved, Investigational
ErythromycinThe serum concentration of Erythromycin can be increased when it is combined with Telmisartan.Approved, Vet Approved
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Telmisartan.Approved
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Telmisartan.Approved, Investigational, Vet Approved
EstriolThe serum concentration of Estriol can be increased when it is combined with Telmisartan.Approved, Vet Approved
EstroneThe serum concentration of Estrone can be increased when it is combined with Telmisartan.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Telmisartan.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Telmisartan is combined with Etanercept.Approved, Investigational
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Telmisartan.Approved
EtodolacThe risk or severity of adverse effects can be increased when Telmisartan is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Telmisartan is combined with Etofenamate.Approved
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Telmisartan.Approved
EtoricoxibThe risk or severity of adverse effects can be increased when Telmisartan is combined with Etoricoxib.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Telmisartan is combined with Evening primrose oil.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Telmisartan.Approved
exisulindThe risk or severity of adverse effects can be increased when Telmisartan is combined with exisulind.Investigational
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Telmisartan.Approved
FelodipineThe risk or severity of adverse effects can be increased when Telmisartan is combined with Felodipine.Approved, Investigational
FenbufenThe risk or severity of adverse effects can be increased when Telmisartan is combined with Fenbufen.Approved
FenoldopamFenoldopam may increase the hypotensive activities of Telmisartan.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Telmisartan is combined with Fenoprofen.Approved
FesoterodineThe serum concentration of Fesoterodine can be increased when it is combined with Telmisartan.Approved
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Telmisartan.Approved
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Telmisartan.Approved
FimasartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Fimasartan.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Telmisartan is combined with Floctafenine.Approved, Withdrawn
FlunixinThe risk or severity of adverse effects can be increased when Telmisartan is combined with Flunixin.Vet Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Telmisartan is combined with Flurbiprofen.Approved, Investigational
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Telmisartan.Approved
FosinoprilThe risk or severity of adverse effects can be increased when Telmisartan is combined with Fosinopril.Approved
FurazolidoneFurazolidone may increase the hypotensive activities of Telmisartan.Approved, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Telmisartan.Approved, Vet Approved
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Telmisartan.Approved, Investigational
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Telmisartan.Approved
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Telmisartan.Approved
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Telmisartan.Withdrawn
GuanabenzGuanabenz may increase the hypotensive activities of Telmisartan.Approved
GuanadrelGuanadrel may increase the hypotensive activities of Telmisartan.Approved
GuanethidineTelmisartan may increase the hypotensive activities of Guanethidine.Approved
GuanfacineThe risk or severity of adverse effects can be increased when Telmisartan is combined with Guanfacine.Approved, Investigational
HaloperidolThe serum concentration of Haloperidol can be increased when it is combined with Telmisartan.Approved
HalothaneThe risk or severity of adverse effects can be increased when Telmisartan is combined with Halothane.Approved, Vet Approved
HeparinHeparin may increase the hyperkalemic activities of Telmisartan.Approved, Investigational
HexamethoniumTelmisartan may increase the hypotensive activities of Hexamethonium.Experimental
HexobarbitalHexobarbital may increase the hypotensive activities of Telmisartan.Approved
HigenamineThe risk or severity of adverse effects can be increased when Telmisartan is combined with Higenamine.Investigational
HMPL-004The risk or severity of adverse effects can be increased when Telmisartan is combined with HMPL-004.Investigational
HydracarbazineHydracarbazine may increase the hypotensive activities of Telmisartan.Approved
HydralazineThe risk or severity of adverse effects can be increased when Telmisartan is combined with Hydralazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Telmisartan is combined with Hydrochlorothiazide.Approved, Vet Approved
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Telmisartan.Approved, Vet Approved
HydroflumethiazideHydroflumethiazide may increase the hypotensive activities of Telmisartan.Approved
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Telmisartan.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Telmisartan is combined with Ibuproxam.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Telmisartan is combined with Icatibant.Approved
IdelalisibThe serum concentration of Idelalisib can be increased when it is combined with Telmisartan.Approved
IloprostIloprost may increase the hypotensive activities of Telmisartan.Approved, Investigational
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Telmisartan.Approved
ImidaprilThe risk or severity of adverse effects can be increased when Telmisartan is combined with Imidapril.Investigational
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Telmisartan.Approved
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Telmisartan.Approved
IndapamideThe risk or severity of adverse effects can be increased when Indapamide is combined with Telmisartan.Approved
IndenololTelmisartan may increase the hypotensive activities of Indenolol.Withdrawn
IndinavirThe serum concentration of Indinavir can be increased when it is combined with Telmisartan.Approved
IndomethacinThe serum concentration of Indomethacin can be increased when it is combined with Telmisartan.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Telmisartan is combined with Indoprofen.Withdrawn
IndoraminTelmisartan may increase the hypotensive activities of Indoramin.Withdrawn
IproclozideIproclozide may increase the hypotensive activities of Telmisartan.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Telmisartan.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Irbesartan.Approved, Investigational
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Telmisartan.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Telmisartan.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Telmisartan is combined with Isoflurane.Approved, Vet Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Telmisartan.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Telmisartan is combined with Isosorbide Mononitrate.Approved
IsoxicamThe risk or severity of adverse effects can be increased when Telmisartan is combined with Isoxicam.Withdrawn
IsoxsuprineThe risk or severity of adverse effects can be increased when Telmisartan is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Telmisartan.Approved
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Telmisartan.Approved, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Telmisartan is combined with Kebuzone.Experimental
KetanserinTelmisartan may increase the hypotensive activities of Ketanserin.Investigational
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Telmisartan.Approved
KetoconazoleThe serum concentration of Ketoconazole can be increased when it is combined with Telmisartan.Approved, Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Telmisartan is combined with Ketoprofen.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Telmisartan is combined with Ketorolac.Approved
LabetalolThe risk or severity of adverse effects can be increased when Labetalol is combined with Telmisartan.Approved
LacidipineTelmisartan may increase the hypotensive activities of Lacidipine.Approved
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Telmisartan.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Telmisartan.Approved, Investigational
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Telmisartan.Approved, Investigational
LatanoprostLatanoprost may increase the hypotensive activities of Telmisartan.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Telmisartan.Approved
LeflunomideThe risk or severity of adverse effects can be increased when Telmisartan is combined with Leflunomide.Approved, Investigational
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Telmisartan.Approved
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Telmisartan.Approved
LercanidipineLercanidipine may increase the hypotensive activities of Telmisartan.Approved, Investigational
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Telmisartan.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Telmisartan is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Telmisartan is combined with Levobupivacaine.Approved
LevodopaTelmisartan may increase the orthostatic hypotensive activities of Levodopa.Approved
LevofloxacinThe serum concentration of Levofloxacin can be increased when it is combined with Telmisartan.Approved, Investigational
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Telmisartan.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Levosimendan.Approved, Investigational
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Telmisartan.Approved
LisinoprilThe risk or severity of adverse effects can be increased when Telmisartan is combined with Lisinopril.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Telmisartan is combined with Lisofylline.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Telmisartan.Approved
LofexidineTelmisartan may increase the hypotensive activities of Lofexidine.Approved, Investigational
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Telmisartan.Approved
LornoxicamThe risk or severity of adverse effects can be increased when Telmisartan is combined with Lornoxicam.Approved
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Telmisartan.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Telmisartan is combined with Loxoprofen.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Telmisartan is combined with Lumiracoxib.Approved, Investigational
MacitentanTelmisartan may increase the hypotensive activities of Macitentan.Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Telmisartan is combined with Magnesium salicylate.Approved
ManidipineTelmisartan may increase the hypotensive activities of Manidipine.Approved
MannitolThe risk or severity of adverse effects can be increased when Mannitol is combined with Telmisartan.Approved, Investigational
MasoprocolThe risk or severity of adverse effects can be increased when Telmisartan is combined with Masoprocol.Approved
MebanazineMebanazine may increase the hypotensive activities of Telmisartan.Withdrawn
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Telmisartan.Approved
Meclofenamic acidThe risk or severity of adverse effects can be increased when Telmisartan is combined with Meclofenamic acid.Approved, Vet Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Telmisartan is combined with Mefenamic acid.Approved
MeloxicamThe risk or severity of adverse effects can be increased when Telmisartan is combined with Meloxicam.Approved, Vet Approved
MesalazineThe risk or severity of adverse effects can be increased when Telmisartan is combined with Mesalazine.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Telmisartan is combined with Metamizole.Withdrawn
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Telmisartan.Approved
MethohexitalMethohexital may increase the hypotensive activities of Telmisartan.Approved
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Telmisartan.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Telmisartan.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Telmisartan is combined with Methyldopa.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Telmisartan.Investigational
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Telmisartan.Approved, Investigational
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Telmisartan.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Telmisartan.Approved, Vet Approved
MetipranololThe risk or severity of adverse effects can be increased when Telmisartan is combined with Metipranolol.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Telmisartan.Approved
MetoprololThe risk or severity of adverse effects can be increased when Metoprolol is combined with Telmisartan.Approved, Investigational
MetyrosineTelmisartan may increase the hypotensive activities of Metyrosine.Approved
MibefradilTelmisartan may increase the hypotensive activities of Mibefradil.Withdrawn
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Telmisartan.Approved, Illicit
MinaprineMinaprine may increase the hypotensive activities of Telmisartan.Approved
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Telmisartan.Approved
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Telmisartan.Approved
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Telmisartan.Approved, Investigational
MizoribineThe risk or severity of adverse effects can be increased when Telmisartan is combined with Mizoribine.Investigational
MoclobemideMoclobemide may increase the hypotensive activities of Telmisartan.Approved
MoexiprilThe risk or severity of adverse effects can be increased when Telmisartan is combined with Moexipril.Approved
MolsidomineMolsidomine may increase the hypotensive activities of Telmisartan.Approved
MorphineThe serum concentration of Morphine can be increased when it is combined with Telmisartan.Approved, Investigational
MoxonidineTelmisartan may increase the hypotensive activities of Moxonidine.Approved
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Telmisartan.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Telmisartan is combined with Mycophenolic acid.Approved
NabiloneThe risk or severity of adverse effects can be increased when Telmisartan is combined with Nabilone.Approved, Investigational
NabumetoneThe risk or severity of adverse effects can be increased when Telmisartan is combined with Nabumetone.Approved
NadololThe risk or severity of adverse effects can be increased when Telmisartan is combined with Nadolol.Approved
NadroparinNadroparin may increase the hyperkalemic activities of Telmisartan.Approved
NafamostatThe risk or severity of adverse effects can be increased when Telmisartan is combined with Nafamostat.Investigational
NaftifineThe risk or severity of adverse effects can be increased when Telmisartan is combined with Naftifine.Approved
NaftopidilTelmisartan may increase the hypotensive activities of Naftopidil.Investigational
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Telmisartan.Approved
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Telmisartan.Approved, Vet Approved
NaproxenThe risk or severity of adverse effects can be increased when Telmisartan is combined with Naproxen.Approved, Vet Approved
NCX 4016The risk or severity of adverse effects can be increased when Telmisartan is combined with NCX 4016.Investigational
NebivololThe risk or severity of adverse effects can be increased when Telmisartan is combined with Nebivolol.Approved, Investigational
NelfinavirThe serum concentration of Nelfinavir can be increased when it is combined with Telmisartan.Approved
NepafenacThe risk or severity of adverse effects can be increased when Telmisartan is combined with Nepafenac.Approved
NesiritideThe risk or severity of adverse effects can be increased when Telmisartan is combined with Nesiritide.Approved, Investigational
NialamideNialamide may increase the hypotensive activities of Telmisartan.Withdrawn
NicardipineThe risk or severity of adverse effects can be increased when Nicardipine is combined with Telmisartan.Approved
NicorandilNicorandil may increase the hypotensive activities of Telmisartan.Approved
NifedipineThe risk or severity of adverse effects can be increased when Telmisartan is combined with Nifedipine.Approved
Niflumic AcidThe risk or severity of adverse effects can be increased when Telmisartan is combined with Niflumic Acid.Approved
NiguldipineTelmisartan may increase the hypotensive activities of Niguldipine.Experimental
NilotinibThe serum concentration of Nilotinib can be increased when it is combined with Telmisartan.Approved, Investigational
NilvadipineTelmisartan may increase the hypotensive activities of Nilvadipine.Approved
NimesulideThe risk or severity of adverse effects can be increased when Telmisartan is combined with Nimesulide.Approved, Withdrawn
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Telmisartan.Approved
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Telmisartan.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Telmisartan.Approved
NitrendipineTelmisartan may increase the hypotensive activities of Nitrendipine.Approved
Nitric OxideThe risk or severity of adverse effects can be increased when Telmisartan is combined with Nitric Oxide.Approved
NitroaspirinThe risk or severity of adverse effects can be increased when Telmisartan is combined with Nitroaspirin.Investigational
NitroglycerinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Telmisartan.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Telmisartan.Approved
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Telmisartan.Approved
ObinutuzumabTelmisartan may increase the hypotensive activities of Obinutuzumab.Approved
OctamoxinOctamoxin may increase the hypotensive activities of Telmisartan.Withdrawn
OlanzapineThe serum concentration of Olanzapine can be increased when it is combined with Telmisartan.Approved, Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Telmisartan.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Telmisartan is combined with Olopatadine.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Telmisartan is combined with Olsalazine.Approved
OmapatrilatThe risk or severity of adverse effects can be increased when Telmisartan is combined with Omapatrilat.Investigational
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Telmisartan.Approved
OrgoteinThe risk or severity of adverse effects can be increased when Telmisartan is combined with Orgotein.Vet Approved
OsimertinibThe serum concentration of Osimertinib can be increased when it is combined with Telmisartan.Approved
OuabainThe serum concentration of Ouabain can be increased when it is combined with Telmisartan.Approved
OxaprozinThe risk or severity of adverse effects can be increased when Telmisartan is combined with Oxaprozin.Approved
OxprenololTelmisartan may increase the hypotensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Telmisartan is combined with Oxyphenbutazone.Withdrawn
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Telmisartan.Approved, Vet Approved
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Telmisartan.Approved, Investigational
PapaverineThe risk or severity of adverse effects can be increased when Telmisartan is combined with Papaverine.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Telmisartan is combined with Parecoxib.Approved
PargylinePargyline may increase the hypotensive activities of Telmisartan.Approved
ParnaparinParnaparin may increase the hyperkalemic activities of Telmisartan.Approved
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Telmisartan.Approved
PenbutololThe risk or severity of adverse effects can be increased when Telmisartan is combined with Penbutolol.Approved, Investigational
PentobarbitalPentobarbital may increase the hypotensive activities of Telmisartan.Approved, Vet Approved
PentoliniumTelmisartan may increase the hypotensive activities of Pentolinium.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Telmisartan.Approved, Investigational
PerindoprilThe risk or severity of adverse effects can be increased when Telmisartan is combined with Perindopril.Approved
PhenelzinePhenelzine may increase the hypotensive activities of Telmisartan.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Telmisartan.Withdrawn
PhenobarbitalThe serum concentration of Phenobarbital can be increased when it is combined with Telmisartan.Approved
PhenoxybenzaminePhenoxybenzamine may increase the hypotensive activities of Telmisartan.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Telmisartan.Withdrawn
PhentolaminePhentolamine may increase the hypotensive activities of Telmisartan.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Telmisartan is combined with Phenylbutazone.Approved, Vet Approved
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Telmisartan.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Telmisartan is combined with Pimecrolimus.Approved, Investigational
PinacidilTelmisartan may increase the hypotensive activities of Pinacidil.Withdrawn
PindololThe risk or severity of adverse effects can be increased when Pindolol is combined with Telmisartan.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Telmisartan is combined with Pipamperone.Approved
PirfenidoneThe risk or severity of adverse effects can be increased when Telmisartan is combined with Pirfenidone.Investigational
PirlindolePirlindole may increase the hypotensive activities of Telmisartan.Approved
PiroxicamThe risk or severity of adverse effects can be increased when Telmisartan is combined with Piroxicam.Approved, Investigational
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Telmisartan.Approved
PivhydrazinePivhydrazine may increase the hypotensive activities of Telmisartan.Withdrawn
PolythiazideTelmisartan may increase the hypotensive activities of Polythiazide.Approved
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Telmisartan.Approved
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Telmisartan.Approved
PramipexoleThe risk or severity of adverse effects can be increased when Telmisartan is combined with Pramipexole.Approved, Investigational
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Telmisartan.Approved
PrazosinThe risk or severity of adverse effects can be increased when Prazosin is combined with Telmisartan.Approved
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Telmisartan.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Telmisartan.Approved, Vet Approved
PrimidonePrimidone may increase the hypotensive activities of Telmisartan.Approved, Vet Approved
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Telmisartan.Approved, Vet Approved
PropacetamolThe risk or severity of adverse effects can be increased when Telmisartan is combined with Propacetamol.Approved
PropofolThe risk or severity of adverse effects can be increased when Telmisartan is combined with Propofol.Approved, Investigational, Vet Approved
PropranololThe risk or severity of adverse effects can be increased when Propranolol is combined with Telmisartan.Approved, Investigational
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Telmisartan.Approved
PTC299The risk or severity of adverse effects can be increased when Telmisartan is combined with PTC299.Investigational
QuetiapineThe risk or severity of adverse effects can be increased when Telmisartan is combined with Quetiapine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Telmisartan is combined with Quinapril.Approved, Investigational
QuinidineThe serum concentration of Quinidine can be increased when it is combined with Telmisartan.Approved
QuinineQuinine may increase the hypotensive activities of Telmisartan.Approved
RamiprilThe risk or severity of adverse effects can be increased when Telmisartan is combined with Ramipril.Approved
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Telmisartan.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Telmisartan.Approved, Investigational
RasagilineRasagiline may increase the hypotensive activities of Telmisartan.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Telmisartan is combined with Remifentanil.Approved
RemikirenRemikiren may increase the hypotensive activities of Telmisartan.Approved
RescinnamineThe risk or severity of adverse effects can be increased when Telmisartan is combined with Rescinnamine.Approved
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Telmisartan.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Telmisartan is combined with Resveratrol.Experimental, Investigational
ReviparinReviparin may increase the hyperkalemic activities of Telmisartan.Approved
RifampicinThe serum concentration of Rifampicin can be increased when it is combined with Telmisartan.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Telmisartan.Approved, Investigational
RilmenidineTelmisartan may increase the hypotensive activities of Rilmenidine.Investigational
RiociguatThe risk or severity of adverse effects can be increased when Telmisartan is combined with Riociguat.Approved
RisperidoneTelmisartan may increase the hypotensive activities of Risperidone.Approved, Investigational
RitonavirThe serum concentration of Ritonavir can be increased when it is combined with Telmisartan.Approved, Investigational
RituximabTelmisartan may increase the hypotensive activities of Rituximab.Approved
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Telmisartan.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Telmisartan is combined with Rofecoxib.Investigational, Withdrawn
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Telmisartan.Approved, Investigational
RopiniroleThe risk or severity of adverse effects can be increased when Telmisartan is combined with Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Telmisartan is combined with Ropivacaine.Approved
RotigotineThe risk or severity of adverse effects can be increased when Telmisartan is combined with Rotigotine.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Telmisartan is combined with Sacubitril.Approved
SafrazineSafrazine may increase the hypotensive activities of Telmisartan.Withdrawn
SalicylamideThe risk or severity of adverse effects can be increased when Telmisartan is combined with Salicylamide.Approved
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Telmisartan.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Telmisartan is combined with Salsalate.Approved
SaprisartanTelmisartan may increase the hypotensive activities of Saprisartan.Experimental
SaquinavirThe serum concentration of Saquinavir can be increased when it is combined with Telmisartan.Approved, Investigational
SecobarbitalSecobarbital may increase the hypotensive activities of Telmisartan.Approved, Vet Approved
SelegilineSelegiline may increase the hypotensive activities of Telmisartan.Approved, Investigational, Vet Approved
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Telmisartan.Approved
SeratrodastThe risk or severity of adverse effects can be increased when Telmisartan is combined with Seratrodast.Approved, Investigational
SevofluraneThe risk or severity of adverse effects can be increased when Telmisartan is combined with Sevoflurane.Approved, Vet Approved
SildenafilSildenafil may increase the antihypertensive activities of Telmisartan.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Telmisartan.Approved
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Telmisartan.Approved
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Telmisartan.Approved, Investigational
SitaxentanTelmisartan may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium NitriteThe risk or severity of adverse effects can be increased when Telmisartan is combined with Sodium Nitrite.Approved
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Telmisartan.Approved
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Telmisartan.Approved, Investigational
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Telmisartan.Approved
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Telmisartan.Approved
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Telmisartan.Experimental
SpiraprilThe risk or severity of adverse effects can be increased when Telmisartan is combined with Spirapril.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Telmisartan.Approved
SRT501The risk or severity of adverse effects can be increased when Telmisartan is combined with SRT501.Investigational
StreptokinaseThe risk or severity of adverse effects can be increased when Telmisartan is combined with Streptokinase.Approved
SufentanilThe risk or severity of adverse effects can be increased when Telmisartan is combined with Sufentanil.Approved, Investigational
SulfasalazineThe risk or severity of adverse effects can be increased when Telmisartan is combined with Sulfasalazine.Approved
SulindacThe risk or severity of adverse effects can be increased when Telmisartan is combined with Sulindac.Approved
SuprofenThe risk or severity of adverse effects can be increased when Telmisartan is combined with Suprofen.Approved, Withdrawn
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Telmisartan.Approved, Investigational
TadalafilTadalafil may increase the antihypertensive activities of Telmisartan.Approved, Investigational
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Telmisartan.Approved
TamsulosinThe risk or severity of adverse effects can be increased when Telmisartan is combined with Tamsulosin.Approved, Investigational
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Telmisartan.Experimental
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Telmisartan.Approved
TelaprevirThe serum concentration of Telaprevir can be increased when it is combined with Telmisartan.Approved
TemocaprilThe risk or severity of adverse effects can be increased when Telmisartan is combined with Temocapril.Experimental, Investigational
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Telmisartan.Approved
TenoxicamThe risk or severity of adverse effects can be increased when Telmisartan is combined with Tenoxicam.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Telmisartan is combined with Tepoxalin.Vet Approved
TerazosinThe risk or severity of adverse effects can be increased when Telmisartan is combined with Terazosin.Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Telmisartan is combined with Teriflunomide.Approved
TerlipressinTelmisartan may increase the hypotensive activities of Terlipressin.Approved, Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Telmisartan is combined with Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThiamylal may increase the hypotensive activities of Telmisartan.Approved, Vet Approved
ThiopentalThiopental may increase the hypotensive activities of Telmisartan.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Telmisartan is combined with Thioridazine.Approved
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Telmisartan is combined with Tiaprofenic acid.Approved
TiboloneTelmisartan may increase the hypotensive activities of Tibolone.Approved
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Telmisartan.Approved
TicrynafenTelmisartan may increase the hypotensive activities of Ticrynafen.Withdrawn
TimololThe risk or severity of adverse effects can be increased when Timolol is combined with Telmisartan.Approved
TinoridineThe risk or severity of adverse effects can be increased when Telmisartan is combined with Tinoridine.Investigational
TinzaparinTinzaparin may increase the hyperkalemic activities of Telmisartan.Approved
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Telmisartan.Approved
TolazolineTolazoline may increase the hypotensive activities of Telmisartan.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Telmisartan is combined with Tolcapone.Approved, Withdrawn
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Telmisartan is combined with Tolfenamic Acid.Approved
TolmetinThe risk or severity of adverse effects can be increased when Telmisartan is combined with Tolmetin.Approved
ToloxatoneToloxatone may increase the hypotensive activities of Telmisartan.Approved
TolvaptanTolvaptan may increase the hyperkalemic activities of Telmisartan.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Telmisartan.Approved, Investigational
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Telmisartan.Approved
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Telmisartan.Approved, Investigational
TrandolaprilThe risk or severity of adverse effects can be increased when Telmisartan is combined with Trandolapril.Approved
TranilastThe risk or severity of adverse effects can be increased when Telmisartan is combined with Tranilast.Approved, Investigational
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Telmisartan.Experimental
TranylcypromineTranylcypromine may increase the hypotensive activities of Telmisartan.Approved
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Telmisartan.Approved
TravoprostTravoprost may increase the hypotensive activities of Telmisartan.Approved
TreprostinilTreprostinil may increase the hypotensive activities of Telmisartan.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Telmisartan is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Telmisartan.Approved
TrichlormethiazideTelmisartan may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrimazosinTelmisartan may increase the hypotensive activities of Trimazosin.Experimental
TrimethaphanTelmisartan may increase the hypotensive activities of Trimethaphan.Approved
TrimethoprimTrimethoprim may increase the hyperkalemic activities of Telmisartan.Approved, Vet Approved
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Telmisartan is combined with Trisalicylate-choline.Approved
UdenafilUdenafil may increase the antihypertensive activities of Telmisartan.Approved, Investigational
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Telmisartan.Approved
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Telmisartan.Approved
UnoprostoneTelmisartan may increase the hypotensive activities of Unoprostone.Approved
ValdecoxibThe risk or severity of adverse effects can be increased when Telmisartan is combined with Valdecoxib.Investigational, Withdrawn
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Telmisartan.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Telmisartan.Approved
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Telmisartan.Approved
VenetoclaxThe serum concentration of Venetoclax can be increased when it is combined with Telmisartan.Approved
VenlafaxineThe serum concentration of Venlafaxine can be increased when it is combined with Telmisartan.Approved
VerapamilThe risk or severity of adverse effects can be increased when Verapamil is combined with Telmisartan.Approved
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Telmisartan.Approved
VincristineThe serum concentration of Vincristine can be increased when it is combined with Telmisartan.Approved, Investigational
VinpocetineTelmisartan may increase the hypotensive activities of Vinpocetine.Investigational
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Telmisartan.Approved
XylometazolineTelmisartan may increase the hypotensive activities of Xylometazoline.Approved
YohimbineYohimbine may decrease the antihypertensive activities of Telmisartan.Approved, Vet Approved
ZaltoprofenThe risk or severity of adverse effects can be increased when Telmisartan is combined with Zaltoprofen.Approved
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Telmisartan.Approved
ZileutonThe risk or severity of adverse effects can be increased when Telmisartan is combined with Zileuton.Approved, Investigational, Withdrawn
ZomepiracThe risk or severity of adverse effects can be increased when Telmisartan is combined with Zomepirac.Withdrawn
Food InteractionsNot Available
References
Synthesis Reference
  1. Kumar AS, Ghosh S, Mehta GN: Efficient and improved synthesis of Telmisartan. Beilstein J Org Chem. 2010 Mar 11;6:25. Pubmed
General References
  1. Sharpe M, Jarvis B, Goa KL: Telmisartan: a review of its use in hypertension. Drugs. 2001;61(10):1501-29. [PubMed:11558835 ]
  2. Smith DH: Treatment of hypertension with an angiotensin II-receptor antagonist compared with an angiotensin-converting enzyme inhibitor: a review of clinical studies of telmisartan and enalapril. Clin Ther. 2002 Oct;24(10):1484-501. [PubMed:12462282 ]
  3. Kumar AS, Ghosh S, Mehta GN: Efficient and improved synthesis of Telmisartan. Beilstein J Org Chem. 2010 Mar 11;6:25. doi: 10.3762/bjoc.6.25. [PubMed:20502601 ]
  4. Galzerano D, Capogrosso C, Di Michele S, Galzerano A, Paparello P, Lama D, Gaudio C: New standards in hypertension and cardiovascular risk management: focus on telmisartan. Vasc Health Risk Manag. 2010 Mar 24;6:113-33. [PubMed:20448797 ]
External Links
ATC CodesC09DB04C09DA07C09CA07
AHFS Codes
  • 24:32.08
PDB EntriesNot Available
FDA labelDownload (47.4 KB)
MSDSDownload (101 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.8794
Caco-2 permeable-0.8957
P-glycoprotein substrateSubstrate0.6061
P-glycoprotein inhibitor INon-inhibitor0.5261
P-glycoprotein inhibitor IIInhibitor0.8653
Renal organic cation transporterNon-inhibitor0.6047
CYP450 2C9 substrateNon-substrate0.7876
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateNon-substrate0.5255
CYP450 1A2 substrateInhibitor0.5699
CYP450 2C9 inhibitorNon-inhibitor0.5481
CYP450 2D6 inhibitorNon-inhibitor0.7796
CYP450 2C19 inhibitorNon-inhibitor0.5509
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.601
Ames testNon AMES toxic0.6432
CarcinogenicityNon-carcinogens0.9094
BiodegradationNot ready biodegradable0.9862
Rat acute toxicity2.8075 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9166
hERG inhibition (predictor II)Non-inhibitor0.7114
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Boehringer ingelheim
Packagers
Dosage forms
FormRouteStrength
TabletOral20 mg
TabletOral40 mg
TabletOral80 mg
TabletOral20 mg/1
TabletOral40 mg/1
TabletOral80 mg/1
TabletOral
Tablet, multilayerOral
Prices
Unit descriptionCostUnit
Micardis 30 40 mg tablet Box110.11USD box
Micardis HCT 30 40-12.5 mg tablet Box106.34USD box
Micardis HCT 30 80-12.5 mg tablet Box106.18USD box
Micardis 30 80 mg tablet Box103.92USD box
Micardis HCT 30 80-25 mg tablet Box100.48USD box
Micardis 30 20 mg tablet Box99.7USD box
Micardis 20 mg tablet3.29USD tablet
Micardis hct 40-12.5 mg tablet3.29USD tablet
Micardis hct 80-12.5 mg tablet3.29USD tablet
Micardis hct 80-25 mg tablet3.29USD tablet
Micardis 40 mg tablet2.24USD tablet
Micardis 80 mg tablet2.24USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2060624 No1999-12-212012-02-04Canada
US5591762 No1994-01-072014-01-07Us
US6358986 No2000-01-102020-01-10Us
US7998953 No2000-06-062020-06-06Us
US8003679 No2002-10-062022-10-06Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point261-263 °CNot Available
water solubilityPractically insolubleNot Available
logP7.7Not Available
Caco2 permeability-4.82ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility0.0035 mg/mLALOGPS
logP6.66ALOGPS
logP6.04ChemAxon
logS-5.2ALOGPS
pKa (Strongest Acidic)3.65ChemAxon
pKa (Strongest Basic)6.13ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area72.94 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity164.49 m3·mol-1ChemAxon
Polarizability58.61 Å3ChemAxon
Number of Rings6ChemAxon
Bioavailability0ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as biphenyls and derivatives. These are organic compounds containing to benzene rings linked together by a C-C bond.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassBiphenyls and derivatives
Direct ParentBiphenyls and derivatives
Alternative Parents
Substituents
  • Biphenyl
  • Benzoic acid
  • Benzoic acid or derivatives
  • Benzimidazole
  • Phenylmethylamine
  • Benzoyl
  • N-substituted imidazole
  • Heteroaromatic compound
  • Imidazole
  • Azole
  • Azacycle
  • Organoheterocyclic compound
  • Monocarboxylic acid or derivatives
  • Carboxylic acid
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
Receptor for angiotensin II. Mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system.
Gene Name:
AGTR1
Uniprot ID:
P30556
Molecular Weight:
41060.53 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Karlberg BE, Lins LE, Hermansson K: Efficacy and safety of telmisartan, a selective AT1 receptor antagonist, compared with enalapril in elderly patients with primary hypertension. TEES Study Group. J Hypertens. 1999 Feb;17(2):293-302. [PubMed:10067800 ]
  3. Balt JC, Mathy MJ, Nap A, Pfaffendorf M, van Zwieten PA: Effect of the AT1-receptor antagonists losartan, irbesartan, and telmisartan on angiotensin II-induced facilitation of sympathetic neurotransmission in the rat mesenteric artery. J Cardiovasc Pharmacol. 2001 Jul;38(1):141-8. [PubMed:11444497 ]
  4. Gohlke P, Weiss S, Jansen A, Wienen W, Stangier J, Rascher W, Culman J, Unger T: AT1 receptor antagonist telmisartan administered peripherally inhibits central responses to angiotensin II in conscious rats. J Pharmacol Exp Ther. 2001 Jul;298(1):62-70. [PubMed:11408526 ]
  5. Strohmenger HU, Lindner KH, Wienen W, Vogt J: Effects of the AT1-selective angiotensin II antagonist, telmisartan, on hemodynamics and ventricular function after cardiopulmonary resuscitation in pigs. Resuscitation. 1997 Aug;35(1):61-8. [PubMed:9259062 ]
  6. Fujimoto M, Masuzaki H, Tanaka T, Yasue S, Tomita T, Okazawa K, Fujikura J, Chusho H, Ebihara K, Hayashi T, Hosoda K, Nakao K: An angiotensin II AT1 receptor antagonist, telmisartan augments glucose uptake and GLUT4 protein expression in 3T3-L1 adipocytes. FEBS Lett. 2004 Oct 22;576(3):492-7. [PubMed:15498586 ]
  7. Sharpe M, Jarvis B, Goa KL: Telmisartan: a review of its use in hypertension. Drugs. 2001;61(10):1501-29. [PubMed:11558835 ]
  8. McClellan KJ, Markham A: Telmisartan. Drugs. 1998 Dec;56(6):1039-44; discussion 1045-6. [PubMed:9878991 ]
  9. Galzerano D, Capogrosso C, Di Michele S, Galzerano A, Paparello P, Lama D, Gaudio C: New standards in hypertension and cardiovascular risk management: focus on telmisartan. Vasc Health Risk Manag. 2010 Mar 24;6:113-33. [PubMed:20448797 ]
  10. Tagami T, Yamamoto H, Moriyama K, Sawai K, Usui T, Shimatsu A, Naruse M: A selective peroxisome proliferator-activated receptor-gamma modulator, telmisartan, binds to the receptor in a different fashion from thiazolidinediones. Endocrinology. 2009 Feb;150(2):862-70. doi: 10.1210/en.2008-0502. Epub 2009 Jan 15. [PubMed:19147680 ]
  11. Imayama I, Ichiki T, Inanaga K, Ohtsubo H, Fukuyama K, Ono H, Hashiguchi Y, Sunagawa K: Telmisartan downregulates angiotensin II type 1 receptor through activation of peroxisome proliferator-activated receptor gamma. Cardiovasc Res. 2006 Oct 1;72(1):184-90. Epub 2006 Jul 21. [PubMed:16938288 ]
  12. Kurtz TW: Beyond the classic angiotensin-receptor-blocker profile. Nat Clin Pract Cardiovasc Med. 2008 Jul;5 Suppl 1:S19-26. doi: 10.1038/ncpcardio0805. [PubMed:18580862 ]
  13. Yamagishi S, Takeuchi M: Telmisartan is a promising cardiometabolic sartan due to its unique PPAR-gamma-inducing property. Med Hypotheses. 2005;64(3):476-8. [PubMed:15617852 ]
  14. Yamagishi S, Nakamura K, Matsui T: Potential utility of telmisartan, an angiotensin II type 1 receptor blocker with peroxisome proliferator-activated receptor-gamma (PPAR-gamma)-modulating activity for the treatment of cardiometabolic disorders. Curr Mol Med. 2007 Aug;7(5):463-9. [PubMed:17691961 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
partial agonist
General Function:
Zinc ion binding
Specific Function:
Nuclear receptor that binds peroxisome proliferators such as hypolipidemic drugs and fatty acids. Once activated by a ligand, the nuclear receptor binds to DNA specific PPAR response elements (PPRE) and modulates the transcription of its target genes, such as acyl-CoA oxidase. It therefore controls the peroxisomal beta-oxidation pathway of fatty acids. Key regulator of adipocyte differentiation...
Gene Name:
PPARG
Uniprot ID:
P37231
Molecular Weight:
57619.58 Da
References
  1. Tagami T, Yamamoto H, Moriyama K, Sawai K, Usui T, Shimatsu A, Naruse M: A selective peroxisome proliferator-activated receptor-gamma modulator, telmisartan, binds to the receptor in a different fashion from thiazolidinediones. Endocrinology. 2009 Feb;150(2):862-70. doi: 10.1210/en.2008-0502. Epub 2009 Jan 15. [PubMed:19147680 ]
  2. Imayama I, Ichiki T, Inanaga K, Ohtsubo H, Fukuyama K, Ono H, Hashiguchi Y, Sunagawa K: Telmisartan downregulates angiotensin II type 1 receptor through activation of peroxisome proliferator-activated receptor gamma. Cardiovasc Res. 2006 Oct 1;72(1):184-90. Epub 2006 Jul 21. [PubMed:16938288 ]
  3. Kurtz TW: Beyond the classic angiotensin-receptor-blocker profile. Nat Clin Pract Cardiovasc Med. 2008 Jul;5 Suppl 1:S19-26. doi: 10.1038/ncpcardio0805. [PubMed:18580862 ]
  4. Yamagishi S, Takeuchi M: Telmisartan is a promising cardiometabolic sartan due to its unique PPAR-gamma-inducing property. Med Hypotheses. 2005;64(3):476-8. [PubMed:15617852 ]
  5. Kurtz TW: Treating the metabolic syndrome: telmisartan as a peroxisome proliferator-activated receptor-gamma activator. Acta Diabetol. 2005 Apr;42 Suppl 1:S9-16. [PubMed:15868121 ]
  6. Yamagishi S, Nakamura K, Matsui T: Potential utility of telmisartan, an angiotensin II type 1 receptor blocker with peroxisome proliferator-activated receptor-gamma (PPAR-gamma)-modulating activity for the treatment of cardiometabolic disorders. Curr Mol Med. 2007 Aug;7(5):463-9. [PubMed:17691961 ]
  7. Yamagishi S, Takenaka K, Inoue H: Role of insulin-sensitizing property of telmisartan, a commercially available angiotensin II type 1 receptor blocker in preventing the development of atrial fibrillation. Med Hypotheses. 2006;66(1):118-20. Epub 2005 Sep 12. [PubMed:16154710 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Weiss J, Sauer A, Divac N, Herzog M, Schwedhelm E, Boger RH, Haefeli WE, Benndorf RA: Interaction of angiotensin receptor type 1 blockers with ATP-binding cassette transporters. Biopharm Drug Dispos. 2010 Mar;31(2-3):150-61. doi: 10.1002/bdd.699. [PubMed:20222053 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Organic anion transmembrane transporter activity
Specific Function:
Mediates hepatobiliary excretion of numerous organic anions. May function as a cellular cisplatin transporter.
Gene Name:
ABCC2
Uniprot ID:
Q92887
Molecular Weight:
174205.64 Da
References
  1. Weiss J, Sauer A, Divac N, Herzog M, Schwedhelm E, Boger RH, Haefeli WE, Benndorf RA: Interaction of angiotensin receptor type 1 blockers with ATP-binding cassette transporters. Biopharm Drug Dispos. 2010 Mar;31(2-3):150-61. doi: 10.1002/bdd.699. [PubMed:20222053 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both from mitochondria to cytosol and from cytosol to extracellular space, and cellular export of hemin, and heme. Xenobiotic transporter that may play an important role in the exclusion of xenobiotics from t...
Gene Name:
ABCG2
Uniprot ID:
Q9UNQ0
Molecular Weight:
72313.47 Da
References
  1. Weiss J, Sauer A, Divac N, Herzog M, Schwedhelm E, Boger RH, Haefeli WE, Benndorf RA: Interaction of angiotensin receptor type 1 blockers with ATP-binding cassette transporters. Biopharm Drug Dispos. 2010 Mar;31(2-3):150-61. doi: 10.1002/bdd.699. [PubMed:20222053 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 02, 2016 02:41